Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2

Benzinga2021-02-18

Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.

In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.

Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.

"As a result, we now operate with a more focused, efficient and competitive cost structure," he said in a prepared statement.

Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'

Q4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021.

In addition, the company reported:

A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019
A cannabis segment revenue increase of 46% to $41.2 million
A net loss of $3 million (it lost $219.8 million for the same period in 2019)
Adjusted EBITDA of $2.2 million
Some $261.3 million in cash as of Feb. 16

A 'New' Tilray: Kennedy cited an "increasingly-favorable political environment," as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.

"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies," he added, touting "significant value for stockholders.”

In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.

Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.

Courtesy image

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Paithorn
2021-02-18
Paithorn
Lovely.
J5385
2021-02-18
J5385
rocket to moon
- J5385:
  yeah
- Paithorn:
  Dont think to moon But should be up
- Basketrif:
  Vested?
LeonardKSW
2021-02-18
LeonardKSW
Hmm
Wangal
2021-02-18
Wangal
Moon
Wangal
2021-02-18
Wangal
?
VicVic3527
2021-02-18
VicVic3527
Tilray worth to hold...

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2112851108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-02-18 07:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2112851108","market":"hk","top_or_hot":-1,"title":"Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2","media":"Benzinga","content":"<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-18 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLRY","symbol_name":"Tilray Inc.","start_time":0,"source_url":"https://www.benzinga.com/node/19716258","article_id":"2112851108","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2112851108","pubTimestamp":1613604297,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Cannabis giant Tilray Inc. (NASDAQ: TLRY) saw revenue climb to $210.5 million in 2020. That&#39;s a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"translate_title":"Tilray报告称2020年营收增长26%，计划在第二季度完成Aphria交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APHA":0.9,"TLRY":1},"content_text":"Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.\nIn Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.\nTilray also reduced costs by about $57 million compared to the same three-month period in 2019.\n\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. \nRelated: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'\nQ4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. \nIn addition, the company reported:\n\nA total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019\nA cannabis segment revenue increase of 46% to $41.2 million\nA net loss of $3 million (it lost $219.8 million for the same period in 2019)\nAdjusted EBITDA of $2.2 million\nSome $261.3 million in cash as of Feb. 16\n\nA 'New' Tilray: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.\n\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”\nIn addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.\nTilray's stock closed at $31.51 and traded up 10% in after-hours trading.\nCourtesy image","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":384959277,"gmtCreate":1613608921499,"gmtModify":1704882638403,"author":{"id":"3574339658121584","authorId":"3574339658121584","name":"Paithorn","avatar":"https://static.tigerbbs.com/30f076bb56b9bb0a0a5dddcb1250f214","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3574339658121584","idStr":"3574339658121584"},"htmlText":"Lovely. &nbsp; &nbsp;","listText":"Lovely. &nbsp; &nbsp;","text":"Lovely.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384959277","repostId":2112851108,"repostType":2,"repost":{"id":"2112851108","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1613604297,"share":"https://ttm.financial/m/news/2112851108?lang=en_US&edition=fundamental","pubTime":"2021-02-18 07:24","market":"hk","language":"en","title":"Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2112851108","media":"Benzinga","summary":"Cannabis giant Tilray Inc. (NASDAQ: TLRY) saw revenue climb to $210.5 million in 2020. That&#39;s a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.","content":"<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-18 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"source_url":"https://www.benzinga.com/node/19716258","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112851108","content_text":"Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.\nIn Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.\nTilray also reduced costs by about $57 million compared to the same three-month period in 2019.\n\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. \nRelated: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'\nQ4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. \nIn addition, the company reported:\n\nA total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019\nA cannabis segment revenue increase of 46% to $41.2 million\nA net loss of $3 million (it lost $219.8 million for the same period in 2019)\nAdjusted EBITDA of $2.2 million\nSome $261.3 million in cash as of Feb. 16\n\nA 'New' Tilray: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.\n\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”\nIn addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.\nTilray's stock closed at $31.51 and traded up 10% in after-hours trading.\nCourtesy image","news_type":1,"symbols_score_info":{"APHA":0.9,"TLRY":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":384963653,"gmtCreate":1613607343172,"gmtModify":1704882613288,"author":{"id":"3573450191379774","authorId":"3573450191379774","name":"J5385","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3573450191379774","idStr":"3573450191379774"},"htmlText":"rocket to moon","listText":"rocket to moon","text":"rocket to moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/384963653","repostId":2112851108,"repostType":2,"repost":{"id":"2112851108","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1613604297,"share":"https://ttm.financial/m/news/2112851108?lang=en_US&edition=fundamental","pubTime":"2021-02-18 07:24","market":"hk","language":"en","title":"Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2112851108","media":"Benzinga","summary":"Cannabis giant Tilray Inc. (NASDAQ: TLRY) saw revenue climb to $210.5 million in 2020. That&#39;s a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.","content":"<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-18 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"source_url":"https://www.benzinga.com/node/19716258","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112851108","content_text":"Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.\nIn Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.\nTilray also reduced costs by about $57 million compared to the same three-month period in 2019.\n\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. \nRelated: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'\nQ4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. \nIn addition, the company reported:\n\nA total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019\nA cannabis segment revenue increase of 46% to $41.2 million\nA net loss of $3 million (it lost $219.8 million for the same period in 2019)\nAdjusted EBITDA of $2.2 million\nSome $261.3 million in cash as of Feb. 16\n\nA 'New' Tilray: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.\n\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”\nIn addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.\nTilray's stock closed at $31.51 and traded up 10% in after-hours trading.\nCourtesy image","news_type":1,"symbols_score_info":{"APHA":0.9,"TLRY":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3600037,"gmtCreate":1613648105735,"gmtModify":1680777378702,"authorId":3573450191379774,"author":{"id":3573450191379774,"idStr":"3573450191379774","authorId":3573450191379774,"name":"J5385","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":384963653,"type":1,"supId":0,"prevId":0,"content":"yeah","text":"yeah","html":"yeah"},{"id":3596095,"gmtCreate":1613612581570,"gmtModify":1680777310448,"authorId":3574339658121584,"author":{"id":3574339658121584,"idStr":"3574339658121584","authorId":3574339658121584,"name":"Paithorn","avatar":"https://static.tigerbbs.com/30f076bb56b9bb0a0a5dddcb1250f214","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":384963653,"type":1,"supId":0,"prevId":0,"content":"Dont think to moon    But should be up ","text":"Dont think to moon    But should be up ","html":"Dont think to moon    But should be up "},{"id":3595676,"gmtCreate":1613609374716,"gmtModify":1680777301922,"authorId":3574715322913604,"author":{"id":3574715322913604,"idStr":"3574715322913604","authorId":3574715322913604,"name":"Basketrif","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":11,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":384963653,"type":1,"supId":0,"prevId":0,"content":"Vested?","text":"Vested?","html":"Vested?"}],"langContent":"EN"},{"id":384960899,"gmtCreate":1613607151911,"gmtModify":1704882610693,"author":{"id":"3569318025811476","authorId":"3569318025811476","name":"LeonardKSW","avatar":"https://static.tigerbbs.com/eeba92ccfc8a91444aa3e36de4a39425","vip":1,"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3569318025811476","idStr":"3569318025811476"},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384960899","repostId":2112851108,"repostType":2,"repost":{"id":"2112851108","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1613604297,"share":"https://ttm.financial/m/news/2112851108?lang=en_US&edition=fundamental","pubTime":"2021-02-18 07:24","market":"hk","language":"en","title":"Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2112851108","media":"Benzinga","summary":"Cannabis giant Tilray Inc. (NASDAQ: TLRY) saw revenue climb to $210.5 million in 2020. That&#39;s a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.","content":"<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-18 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"source_url":"https://www.benzinga.com/node/19716258","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112851108","content_text":"Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.\nIn Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.\nTilray also reduced costs by about $57 million compared to the same three-month period in 2019.\n\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. \nRelated: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'\nQ4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. \nIn addition, the company reported:\n\nA total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019\nA cannabis segment revenue increase of 46% to $41.2 million\nA net loss of $3 million (it lost $219.8 million for the same period in 2019)\nAdjusted EBITDA of $2.2 million\nSome $261.3 million in cash as of Feb. 16\n\nA 'New' Tilray: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.\n\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”\nIn addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.\nTilray's stock closed at $31.51 and traded up 10% in after-hours trading.\nCourtesy image","news_type":1,"symbols_score_info":{"APHA":0.9,"TLRY":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":384989369,"gmtCreate":1613606440451,"gmtModify":1704882598487,"author":{"id":"3575580168546148","authorId":"3575580168546148","name":"Wangal","avatar":"https://static.tigerbbs.com/800f70a7feba8b3bc44da842ec3567a6","vip":1,"crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3575580168546148","idStr":"3575580168546148"},"htmlText":"Moon","listText":"Moon","text":"Moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384989369","repostId":2112851108,"repostType":2,"repost":{"id":"2112851108","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1613604297,"share":"https://ttm.financial/m/news/2112851108?lang=en_US&edition=fundamental","pubTime":"2021-02-18 07:24","market":"hk","language":"en","title":"Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2112851108","media":"Benzinga","summary":"Cannabis giant Tilray Inc. (NASDAQ: TLRY) saw revenue climb to $210.5 million in 2020. That&#39;s a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.","content":"<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-18 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"source_url":"https://www.benzinga.com/node/19716258","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112851108","content_text":"Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.\nIn Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.\nTilray also reduced costs by about $57 million compared to the same three-month period in 2019.\n\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. \nRelated: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'\nQ4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. \nIn addition, the company reported:\n\nA total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019\nA cannabis segment revenue increase of 46% to $41.2 million\nA net loss of $3 million (it lost $219.8 million for the same period in 2019)\nAdjusted EBITDA of $2.2 million\nSome $261.3 million in cash as of Feb. 16\n\nA 'New' Tilray: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.\n\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”\nIn addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.\nTilray's stock closed at $31.51 and traded up 10% in after-hours trading.\nCourtesy image","news_type":1,"symbols_score_info":{"APHA":0.9,"TLRY":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":384911465,"gmtCreate":1613605793957,"gmtModify":1704882588589,"author":{"id":"3575580168546148","authorId":"3575580168546148","name":"Wangal","avatar":"https://static.tigerbbs.com/800f70a7feba8b3bc44da842ec3567a6","vip":1,"crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3575580168546148","idStr":"3575580168546148"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384911465","repostId":2112851108,"repostType":2,"repost":{"id":"2112851108","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1613604297,"share":"https://ttm.financial/m/news/2112851108?lang=en_US&edition=fundamental","pubTime":"2021-02-18 07:24","market":"hk","language":"en","title":"Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2112851108","media":"Benzinga","summary":"Cannabis giant Tilray Inc. (NASDAQ: TLRY) saw revenue climb to $210.5 million in 2020. That&#39;s a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.","content":"<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-18 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"source_url":"https://www.benzinga.com/node/19716258","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112851108","content_text":"Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.\nIn Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.\nTilray also reduced costs by about $57 million compared to the same three-month period in 2019.\n\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. \nRelated: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'\nQ4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. \nIn addition, the company reported:\n\nA total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019\nA cannabis segment revenue increase of 46% to $41.2 million\nA net loss of $3 million (it lost $219.8 million for the same period in 2019)\nAdjusted EBITDA of $2.2 million\nSome $261.3 million in cash as of Feb. 16\n\nA 'New' Tilray: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.\n\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”\nIn addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.\nTilray's stock closed at $31.51 and traded up 10% in after-hours trading.\nCourtesy image","news_type":1,"symbols_score_info":{"APHA":0.9,"TLRY":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":384901197,"gmtCreate":1613602184719,"gmtModify":1704882546071,"author":{"id":"3575073792751116","authorId":"3575073792751116","name":"VicVic3527","avatar":"https://static.tigerbbs.com/bda7fa213d1bbf7a7c7ffe74e08d9e71","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3575073792751116","idStr":"3575073792751116"},"htmlText":"Tilray worth to hold...&nbsp;","listText":"Tilray worth to hold...&nbsp;","text":"Tilray worth to hold...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/384901197","repostId":2112851108,"repostType":2,"repost":{"id":"2112851108","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1613604297,"share":"https://ttm.financial/m/news/2112851108?lang=en_US&edition=fundamental","pubTime":"2021-02-18 07:24","market":"hk","language":"en","title":"Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2112851108","media":"Benzinga","summary":"Cannabis giant Tilray Inc. (NASDAQ: TLRY) saw revenue climb to $210.5 million in 2020. That&#39;s a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.","content":"<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-18 07:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Cannabis giant <strong><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></strong> (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.</p>\n<p>In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.</p>\n<p>Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.</p>\n<p>\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. </p>\n<p><em>Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'</em></p>\n<p><strong>Q4 Breakdown</strong>: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company <strong><a href=\"https://laohu8.com/S/APHA\">Aphria Inc.</a></strong> (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. </p>\n<p>In addition, the company reported:</p>\n<ul>\n<li>A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019</li>\n<li>A cannabis segment revenue increase of 46% to $41.2 million</li>\n<li>A net loss of $3 million (it lost $219.8 million for the same period in 2019)</li>\n<li>Adjusted EBITDA of $2.2 million</li>\n<li>Some $261.3 million in cash as of Feb. 16</li>\n</ul>\n<p><strong>A 'New' Tilray</strong>: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.</p>\n<p>\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”</p>\n<p>In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.</p>\n<p>Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.</p>\n<p><em>Courtesy image</em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","APHA":"Aphria Inc."},"source_url":"https://www.benzinga.com/node/19716258","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112851108","content_text":"Cannabis giant Tilray Inc. (NASDAQ:TLRY) saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.\nIn Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.\nTilray also reduced costs by about $57 million compared to the same three-month period in 2019.\n\"As a result, we now operate with a more focused, efficient and competitive cost structure,\" he said in a prepared statement. \nRelated: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'\nQ4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. (NASDAQ:APHA). The deal should wrap in the second quarter of 2021. \nIn addition, the company reported:\n\nA total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019\nA cannabis segment revenue increase of 46% to $41.2 million\nA net loss of $3 million (it lost $219.8 million for the same period in 2019)\nAdjusted EBITDA of $2.2 million\nSome $261.3 million in cash as of Feb. 16\n\nA 'New' Tilray: Kennedy cited an \"increasingly-favorable political environment,\" as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.\n\"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies,\" he added, touting \"significant value for stockholders.”\nIn addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.\nTilray's stock closed at $31.51 and traded up 10% in after-hours trading.\nCourtesy image","news_type":1,"symbols_score_info":{"APHA":0.9,"TLRY":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":8,"commentSize":6,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2112851108","isCrawlerRequest":true}